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value-based pricing, which reflects disease burden, therapeutic innovation, and 
social values, is suggested. This study attempts to measure the importance of cost-
effectiveness and other values for a new anticancer drug. Methods: Through 
literature reviews and experts’ advices, eight health insurance benefit criteria 
were selected: disease severity, size of population affected by disease, pediatric 
medicine, alternative drugs, innovativeness, clinical benefit, cost-effectiveness, and 
budget impact. Preference for the criteria was investigated by using Discrete Choice 
Experiments(DCE), Analytic Hierarchy Process (AHP), swing weighting (SWING), and 
direct point allocation (DIRECT). The survey was conducted in three hundred general 
population through face to face interview. Respondents were selected using strati-
fied random sampling by age, sex and region. The conditional logistic regression for 
DCE was conducted with STATA ver.12. Results: In the preference investigation 
using DCE, people preferentially considered disease severity (OR: 1.837, 95% CI: 1.673 
to 2.017), alternative drugs (OR: 1.556, 95% CI: 1.458 to 1.661), and size of population 
affected by disease (OR: 1.408, 95% CI: 1.285 to 1.543). According to the results by 
using AHP, respondents considered clinical benefit to be the most important, fol-
lowed by cost-effectiveness and disease severity as the main evaluation items. As 
estimated by SWING and DIRECT, clinical benefit was also evaluated as the most 
important item. There was no difference in the first to third priority evaluation 
items between SWING and DIRECT. ConClusions: The priorities derived from all 
methodologies show that clinical benefit and disease severity were more important 
than cost-effectiveness in general terms. In the situation where decision-making is 
mostly centered on cost-effectiveness, our results may be seen as the social demand 
that clinical benefit and the influence of applicable disease should be reflected 
appropriately in the insurance coverage.
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objeCtives: The aim of our study is to analyse the biosimilar bids of the Hungarian 
National Health Insurance Fund Administration in case of colony-stimulating fac-
tor (CSF) products. Methods: Data derived from the nationwide pharmaceutical 
database of Hungarian National Health Insurance Fund Administration (NHIFA). We 
analysed how the number of patients treated by colony-stimulating factor products 
changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2014.) the first 
biosimilar bid performed in March 2012 in Hungary. Results: In the 12 months 
before biosimilar bid 27,367 patients received colony-stimulating factor treatment, 
while in the first 12 months after the bid 26,149 patients, resulting in a 4.5 % decline. 
The second 12 months after the bid 28,463 patients received colony-stimulating 
factor treatment, resulting in a 4.0 % increase. Before the biosimilar bid, the NHIFA 
spent 7.49 billion Hungarian Forint (HUF) health insurance reimbursement for CSF 
products, which decreased by 44 % to 4.19 billion HUF in the first year after bio-
similar bid. ConClusions: The analyses of the Hungarian price competition bid 
of biosimilar products showed a minimal decline in the number of patients under 
treatment by colony-stimulating factor products while the health insurance reim-
bursement of these drugs significantly decreased.
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objeCtives: To assess the ability of G-CSF (Granulocyte-Colony Stimulating Factors) 
biosimilars (G-CSF-BIOSIM) to compete with their reference (REF) within the same 
therapeutic class by analyzing EU-5 and Japanese G-CSF markets and the factors 
influencing G-CSF-BIOSIM uptakes, 3 years after a same analysis carried out in 
2011. Methods: Data on medicine volumes, values and ex-manufacturer prices for 
all G-CSF categories in the EU-5 and in Japan were provided by IMS Health. Volumes 
were calculated in DDD (Defined Daily Doses) and prices in euros per DDD. Results: 
There are two G-CSF market profiles: i) countries with a high retail market distribu-
tion (R) which are the largest G-CSF markets with low global G-CSF-BIOSIM uptakes 
(11.8% in France and 12.8% in Germany); ii) countries with a dominant hospital chan-
nel (H) which are the smallest markets with higher G-CSF-BIOSIM uptakes (56.8% in 
Spain, 40.7% in the UK and 25.2% in Italy). Japan is a special case: H market and 12.0% 
G-CSF-BIOSIM uptakes (G-CSF-BIOSIM arrived latter in Japan than in Europe). The 
G-CSF-BIOSIM uptakes depend critically on their market access at a local/regional 
level. The more the decisions are decentralized (hospitals, local purchasing structures) 
the more their uptakes are high (51.4% of the hospital market in France and 40.7% 
in the UK). The price discount between G-CSF-BIOSIM and REF plays a marginal role 
globally (-7.8% in France, and +12.2% in the UK). ConClusions: Global G-CSF-BIOSIM 
uptakes sharply increased in EU-5 countries between 2011 and 2014 (e.g. +358% in 
Spain in volume, +119% in France). We confirm the results of our first study: there 
are two G-CSF market profiles and the competition with G-CSF-BIOSIM is not mainly 
based on prices, but on local political options. The study should now be extended to 
other countries to definitively validate these results.
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Council’ (Australia, December 2005) was chosen by the working group as one of 
key prototypes of the best medical practice in lymphoma patients on evidence-
based medicine. The working group has conducted an additional search for original 
sources of scientific information in order to justify the choice of CT. The results of 
search were presented as evidence tables according to the efficacy of various CT 
regimes. In general, 56 sources have been analyzed. Results: Clinical protocols in 
lymphoma patients with taking into account the obtained data have been devel-
oped. They included medical technologies with proven efficacy. However, it should 
be noted that some of the CT schemes with sufficient efficacy in clinical trials in 
patients with recurrent and refractory forms of lymphoma, high grade of aggressive 
non-Hodgkin lymphoma include bortezomib, vinorelbine, gemcitabine, carboplatin, 
cisplatin. These agents are not licensed for lymphoma, that results in impossibility 
to prescribe such regimes to patients. ConClusions: The up-to-date CT regimes 
allow achieving better results. However, the treatment is expensive, but prolongs 
survival and improves quality of life. Thus, introduction of modern approaches 
to the treatment of lymphomas in Ukraine and harmonization of Ukrainian and 
world’s practices will provide comprehensive and effective medical care for patients.
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objeCtives: Breast cancer is the most common cancer in women in England and 
the second most common cause of cancer death. In 2011, there were > 40,000 new 
breast cancer cases and > 10,000 deaths, with delay to diagnosis thought to be an 
attributing factor. Our aim was to map out the breast cancer diagnostic pathways for 
women in England, quantify the number of women proceeding through each step 
of the pathway, and compare it to the pathway in France and Germany. Methods: 
We performed literature searches for peer-reviewed papers and other published 
data from England, and conducted semi-structured interviews with cancer experts 
to understand the breast cancer diagnostic process. A patient pathway framework 
for diagnosis was modelled in Microsoft Excel and patient flow was quantified 
with published data and our own calculations where there were missing data. We 
validated the model with data from France and Germany. Results: England’s 
well-organised National Health Service Breast Screening Programme (NHSBSP) 
identifies women with early stage breast cancer to manage them promptly. Whilst 
NHSBSP coverage is 75% of invited women, only 40% of all malignancies are identi-
fied through screening, with the remaining cases from symptomatic referrals to 
breast services. We estimated that ~230,000 women present in general practice with 
breast symptoms annually and are referred to breast services, an estimated 46,000 
symptomatic women have biopsies, yielding 24,528 malignant cases. The ratio of 
women attending breast services, having a biopsy, and having a malignancy differ 
between screened and symptomatic women. The diagnostic pathway is similar in 
France and Germany, although the proportion identified through screening dif-
fers. ConClusions: Data on the full breast cancer diagnostic pathway are sparse, 
especially for women with symptoms. Our complete diagnostic pathway gives a full 
understanding about the diagnostic process, tests conducted, and quantifies the 
burden on healthcare services.
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objeCtives: Radiation oncologists and radiation therapists are key medical 
personnel involved with radiation therapy (RT). The objective was to determine 
costs associated with RT-personnel using provincial (Ontario) administrative data-
bases. Methods: A cohort of women diagnosed with primary breast cancer (BC) 
(ICD-9 174.x) was identified from the Ontario Cancer Registry (2007-2010) with up 
to one year follow-up timeframe. Radiation oncologists bill patient visits to the 
Ontario Health Insurance Plan (OHIP). Visits with $0 charge were excluded. Radiation 
therapists record planning and treatment workloads (conventional and intensity 
modulated RT or IMRT) using National Health Productivity Improvement Program 
(NHPIP) activity codes in the Activity Level Reporting (ALR) database. An hourly 
wage was then applied to these codes to determine costs within the first year 
after diagnosis. Results: We identified 30,338 women diagnosed with primary BC, 
86% (N= 26,121) of whom visited a radiation oncologist. The average cost of these 
visits per patient was $1,013 ± $607. The total number of visits was 165,060 and the 
total cost was $26.5 million. Approximately 62% of the cohort received planning 
(N= 18,859) and treatment (N= 18,758) for conventional RT by radiation therapists and 
the average cost per patient was $479 ± $326 and $282 ± $176, respectively. The total 
planning and treatment cost for conventional RT was $9.0 million and $5.3 million, 
respectively. For IMRT planning (N= 1,631) and treatment (N= 5,883), the average cost 
per patient was $158 ± $84 and $637 ± $297, respectively. The total planning and 
treatment cost for IMRT was $258,239 and $3.7 million, respectively. The overall cost 
of radiation oncologist and RT visits was $44.8 million. ConClusions: Personnel 
costs for delivering RT to breast cancer patients in the first year after their diagno-
sis are significant. Future work will be to incorporate the cost of other personnel 
involved with RT, such as medical physicists and nurses.
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objeCtives: The cost-effectiveness, based on economic evaluation, has been 
an important basis for reimbursement decisison making in Korea. Recently, the 
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Cheshire, Warrington and Wiral (12,091mg) –18.2 fold difference. Imatinib, highest: 
East Anglia (370,461mg); lowest: Leicestershire and Lincolnshire (71,592mg) –5.2 
fold difference. Denosumab, highest: Cheshire, Warrington and Wiral (11,281DDD); 
lowest: Merseyside (0DDD). ConClusions: There are large variations in local pre-
scribing between different NICE-approved oncology drugs, which exceeds what 
might have been expected from variations in local demographics. The ongoing frag-
mentation of the NHS particularly with respect to specialised service provision will 
likely further exacerbate this geographical variability in coverage and potentially 
fuel a greater ‘postcode lottery.’
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objeCtives: To review evidence-based processes used in UK cancer fund-
ing decisions, using biologics in metastatic colorectal cancer (mCRC) as a case 
study. Methods: We conducted an analysis of the peer-reviewed literature report-
ing overall survival (OS) in mCRC in randomised clinical trials (RCTs) and in real 
world studies (RWSs). Additionally, we investigated the use of RCTs and RWSs in UK 
cancer drug funding decisions. Results: Recent RWSs report median OS levels in 
mCRC that are several months longer than those seen in pre-biologic RCTs (approxi-
mately 29.2 months in the post-biologic era versus 17.4 months pre-biologics, an 
incremental survival benefit of 11.8 months). The most recent data show real world 
median OS as long as 32 months. However, the scoring system for cancer funding 
decisions in the UK is currently predominantly focused on pre-launch RCT data, 
with no data drawn from RWSs referenced in National Institute for Health and Care 
Excellence (NICE) and Clinical Reference Group (CRG) evaluations. ConClusions: 
The current focus of the cancer funding scoring system on pre-launch RCTs may 
miss value gained from ‘innovation-in-use.’ Additionally, treatment holidays and 
sequencing steps could lead to further cost reductions that might increase value 
even without impact on OS. Therefore, NICE evaluations and the methodology for 
CRG scoring may undervalue the reality of real-world experience. The Cancer Drugs 
Fund (CDF) enables the UK National Health Service to realize the full scope of ben-
efits of innovative drugs, overcoming the deficiencies currently inherent in NICE and 
CRG processes. Therefore, considerations for delisting of drugs from the CDF should 
be made in the light of data from RWSs as well as pre-launch data.
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objeCtives: Spending on oncology medications accounts for a growing share of 
total medical spending, raising questions about the financial sustainability of 
pricing regimes and continued progress against cancer. This research evaluates oncol-
ogy spending across product classes, shedding light on the impact of loss of exclu-
sivity (LOE) and new product entry in order to provide focus and an improved fact 
basis for discussions of financial sustainability in oncology treatment. Methods: 
Quarterly observations on national-level sales of oncology medication in each of the 
five largest European markets, the US and Japan are compiled from IMS Health data 
from 2001 to 2013. These data are evaluated by medication type (cytotoxics, hormonals 
and targeted therapies) and brand/generic/biologic status, to evaluate the impact of 
LOE and new product entry with an eye toward projecting future oncology spending. 
Spending levels on oncology products by therapy type, country and exclusivity status 
are juxtaposed with patterns of hyperlipidemia and anti-ulcer products to assess the 
differences in sales patterns as product classes mature and lose exclusivity. Results: 
Although there is considerable variation across countries, it is generally observed that 
small-molecule oncologic products experience a classic “patent cliff” around LOE. For 
example, total spending on cytotoxics (chemotherapy agents) in the US peaked in 
late 2011 and declined to 83% of peak levels by late 2013; generics comprised 12% of 
total spending in 2001, and 28% of total spending by late 2013. Targeted therapies, on 
the other hand, have experienced consistent sales growth, with much of that growth 
occurring for biologic therapies. ConClusions: Oncology spending in major global 
markets does not appear to be fundamentally unsustainable. Questions about future 
spending growth are appropriately focused on targeted therapies, particularly on 
biologic products, suggesting that the emergence of biosimilars will play a central 
role in shaping oncology spending in coming years.
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objeCtives: To characterise UK Cancer Drug Fund (CDF) scoring of breast can-
cer drugs using the CDF prioritisation tool and to assess the final decisions made 
by the Chemotherapy Clinical Reference Group (CCRG) and the national CDF 
panel. Methods: The CDF decision summaries (available online at www.england.
nhs.uk/ourwork/pe/cdf/cdf-drug-sum) record the formal decisions of the CCRG in 
relation to drugs and drug indications that are reviewed for inclusion on the national 
CDF list. We reviewed the individual scoring for each treatment in the criteria using 
the CDF prioritisation tool. Assessed criteria included: magnitude of survival benefit 
(progression free survival and overall survival), quality of life, toxicity compared 
with existing therapies, degree of unmet clinical need, strength of evidence and 
total score. Results: Between April 2013 and May 2015, 15 decision summaries 
assessing 7 drugs for the treatment of breast cancer were reported by the CCRG. Of 
these summaries, 5 saw a positive overall decision and 10 were negative. The over-
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objeCtives: MCDA allows structured consideration of the many aspects of value 
appraisal in healthcare. This study explored the value of lenvatinib for RR-DTC using 
holistic MCDA (EVIDEM framework). Methods: The framework integrated 12 quan-
titative and 7 qualitative contextual criteria, each derived from fundamental ethical 
positions. By-criterion lenvatinib evidence matrices were designed for three countries 
(France, Italy, Spain) and two comparators (watch and wait, sorafenib) based on a 
systematic review and proprietary data. Value appraisal was performed by collecting 
weights (individual perspectives), scores (performance of lenvatinib) and qualitative 
inputs (impact of context) from three structured panel sessions designed to include 
patients, physicians, health economists and policy-decisionmakers, convened under 
the Chatham house rule. Value contributions (WeightsXScores) for each criterion and 
variability across individuals, countries and weighting methods were analyzed. Data 
on usefulness of the process were collected. Results: The greatest weights were 
given to criteria Comparative effectiveness together with Quality of evidence (Spain 
and Italy) or Disease severity (France). Across all countries and comparators, four cri-
teria contributed most to the value of lenvatinib (Comparative effectiveness [16-22%], 
Disease severity [16-22%], Unmet needs [14-21%], Quality of evidence [14-20%]), with 
contributions varying by comparator and country. Some negative contributions were 
observed for criteria Comparative safety (versus watch and wait) and Comparative 
economic consequences. The overall value of lenvatinib was positive across countries 
and comparators with variability across individuals, countries and weighting meth-
ods. Impacts of contextual criteria varied noticeably across countries, highlighting 
the importance of local consultation. Panelists reported the process contributed to 
their understanding of the intervention and its context and was helpful to express 
and share their perspectives and knowledge. ConClusions: Using MCDA-based 
holistic appraisal, the value of lenvatinib was assessed as consistently positive in the 
diverse treatment landscapes. The method provides a structured means to collect 
country-specific data and facilitates exchange across stakeholders.
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objeCtives: Cost-per-QALY (CPQ) threshold can be a useful tool for resource alloca-
tion decisions but also may constitute an obstacle in access to the most-innovative, 
often life-saving but also expensive medicines. Since cancer is a major challenge 
for all healthcare systems, we investigated the impact of CPQ policy on new cancer 
drug reimbursement in 6 Central and Eastern Europe (CEE) countries: Poland and 
Slovakia (CPQ-driven countries), Czech Republic and Hungary (CPQ-oriented coun-
tries), Croatia and Romania (non-CPQ countries). Methods: Basing on predefined 
criteria we selected 13 drug-indication pairs and considered their reimbursement 
status, time from registration to positive reimbursement decision and possible 
factors influencing reimbursement decision. Analyzes were performed for each 
selected country separately and in pairs grouped with regard to CPQ policy. The 
results were compared with indicators illustrating reimbursement systems, general 
cancer care and economics of participating countries. Results: Generally, in all 
participating countries, cancer drugs generating lower CPQ values were more likely 
to be reimbursed. Analysis based on multinomial model adjusting for factors that 
might impact reimbursement decision confirmed significant role of CPQ value of 
a drug and GDP per capita of a country. Medicines generating higher CPQ values or 
evaluated in countries with lower GDP per capita are less likely to obtain positive 
reimbursement decisions. ConClusions: CEE countries have a different approach 
to CpQ application in reimbursement decisions. Access to oncology treatment for 
patients in CEE seems to be affected and not necessary improved by CPQ imple-
mentation policy. Higher CPQ value results in more constrained access to cancer 
drugs and prolonged time to reimbursement decision. CPQ is not the only criterion 
in the reimbursement process and even when met does not inevitably transfer into 
positive reimbursement decision. It seems that currently factors related to economy 
of CEE countries may affect reimbursement by far more than strictly CPQ policy.
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objeCtives: Access to drugs, particularly high cost oncology medicines, across 
England has frequently been accused to operate under a ‘postcode lottery’ where 
access varied depending on where you live. Since 2012, the National Institute of 
Health and Care Excellence (NICE) recommendations are mandated to be followed 
nationally within 90 days of issuing. Nevertheless, further regional/local restrictions 
upon usage are not uncommon that, along with the duration of NICE decision-
making and non-universal coverage of medicines by NICE, leads to variability in 
prescribing levels of high cost medicines. Furthermore, NHS commissioning of 
specialised services is moving towards increasing co-commissioning between the 
local Clinical Commissioning Group (CCG) teams and regional/local NHS England 
bodies (formally Area Teams), with diverse models of care and service specifica-
tions being set out as part of the NHS 5 Year Forward View. This research aims to 
evaluate the level of regional variation in NHS prescribing. Methods: All cancer 
drug prescribing data from the most recent NHS innovation scorecard heat map 
(July-September 2014) was extracted. Variations in prescribing across the 25 Area 
Teams per 100,000 population were identified. Results: Data for three oncology 
drugs was available: denosumab, imatinib and nilotinib; NICE has issued positive 
guidance for all of these. Stark variations in amount prescribed between differ-
ent area teams were apparent. Nilotinib, highest: Merseyside (220,385mg); lowest: 
